Suppr超能文献

相似文献

3
Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma.
J Hematol Oncol. 2016 Mar 29;9:30. doi: 10.1186/s13045-016-0260-7.
5
3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Cell Cycle. 2009 Nov 1;8(21):3592-600. doi: 10.4161/cc.8.21.9993. Epub 2009 Nov 3.
7
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma.
Biomark Res. 2017 May 8;5:16. doi: 10.1186/s40364-017-0094-7. eCollection 2017.
8
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
Blood. 2008 Aug 1;112(3):822-9. doi: 10.1182/blood-2008-03-142182. Epub 2008 May 15.

引用本文的文献

1
Alternative cleavage and polyadenylation: key regulatory mechanisms in health and disease.
RNA Biol. 2025 Dec;22(1):1-33. doi: 10.1080/15476286.2025.2529033. Epub 2025 Jul 9.
2
Identification and characterization of eccDNA-driven genes in humans.
PLoS One. 2025 Jun 6;20(6):e0324438. doi: 10.1371/journal.pone.0324438. eCollection 2025.
3
Characterization and molecular targeting of CFIm25 (NUDT21/CPSF5) mRNA using miRNAs.
FASEB J. 2025 Jan 31;39(2):e70324. doi: 10.1096/fj.202402184R.
5
Fateful Decisions of Where to Cut the Line: Pathology Associated with Aberrant 3' End Processing and Transcription Termination.
J Mol Biol. 2025 Jan 1;437(1):168802. doi: 10.1016/j.jmb.2024.168802. Epub 2024 Sep 24.
6
The roles and mechanisms of coding and noncoding RNA variations in cancer.
Exp Mol Med. 2024 Sep;56(9):1909-1920. doi: 10.1038/s12276-024-01307-x. Epub 2024 Sep 2.
7
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
Blood Adv. 2024 Jul 23;8(14):3652-3664. doi: 10.1182/bloodadvances.2023011763.
8
Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview.
Hematol Rep. 2024 Mar 21;16(1):164-178. doi: 10.3390/hematolrep16010017.
10
[IGL-CCND1 positive mantle cell lymphoma: a case report and literature review].
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):598-601. doi: 10.3760/cma.j.issn.0253-2727.2023.07.015.

本文引用的文献

2
Cyclin D1: polymorphism, aberrant splicing and cancer risk.
Oncogene. 2006 Mar 13;25(11):1620-8. doi: 10.1038/sj.onc.1209371.
3
4
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5. doi: 10.1073/pnas.0506281103. Epub 2006 Feb 6.
5
The widespread impact of mammalian MicroRNAs on mRNA repression and evolution.
Science. 2005 Dec 16;310(5755):1817-21. doi: 10.1126/science.1121158. Epub 2005 Nov 24.
6
Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma.
Leuk Res. 2006 Apr;30(4):497-501. doi: 10.1016/j.leukres.2005.08.026. Epub 2005 Oct 3.
7
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
J Clin Oncol. 2005 Aug 10;23(23):5347-56. doi: 10.1200/JCO.2005.13.466. Epub 2005 Jun 27.
8
Combinatorial microRNA target predictions.
Nat Genet. 2005 May;37(5):495-500. doi: 10.1038/ng1536. Epub 2005 Apr 3.
9
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals.
Nature. 2005 Mar 17;434(7031):338-45. doi: 10.1038/nature03441. Epub 2005 Feb 27.
10
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.
Nature. 2005 Feb 17;433(7027):769-73. doi: 10.1038/nature03315. Epub 2005 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验